Immunic AG Announces Participation in May Conferences for Investor and Scientific Communities

Immunic, Inc. (Nasdaq: IMUX), a developer of small molecule therapies for chronic inflammatory and autoimmune diseases, has revealed its participation in multiple conferences scheduled for May 2024. These events are key for both investor relations and scientific advancements. Immunic's representatives will engage in strategic meetings and present critical data at these global gatherings.

The company has scheduled attendance at Bio€quity Europe 2024 from May 12-14 and 21-22 in San Sebastián, Spain, and online. Key company figures will conduct investor meetings, which interested parties can schedule through the conference portal. Furthermore, significant trial data will be presented at the Digestive Disease Week in Washington, DC, highlighting findings from Immunic's phase 1b study of IMU-856 in treating celiac disease. This presentation is slotted for May 18-21.

Later in the month, at the Consortium of Multiple Sclerosis Centers' annual meeting in Nashville, TN, preliminary results from the phase 2 CALLIPER trial of IMU-838 will be discussed. Additionally, Immunic will present at the XXIII National Congress of Neurology in Bulgaria from May 30 - June 1, focusing on a phase 2 trial assessing IMU-838 in progressive multiple sclerosis.